XOMA Royalty (XOMA) Short-term Investments (2012 - 2026)
XOMA Royalty (XOMA) reported Short-term Investments of $494000.0 for Q1 2026, down 79.26% on a YoY basis from $2.4 million in Q1 2025, and up 23.5% sequentially from $400000.0 in Q4 2025.
XOMA Royalty (XOMA) Short-term Investments (2012 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 12 years of Short-term Investments data on file, last reported at $494000.0 in Q1 2026.
- For the quarter ending Q1 2026, Short-term Investments fell 79.26% year-over-year to $494000.0; the trailing twelve-month figure through Mar 2026 stood at $494000.0 (down 79.26% YoY), and the FY2025 full-year result was $400000.0, down 69.92% from the prior year.
- Short-term Investments grew to $494000.0 in Q1 2026, from $400000.0 in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $5.2 million in Q3 2025 to a low of $80000.0 in Q2 2025.
- A 5-year average of $850823.5 and a median of $443000.0 in 2022 frame the typical range for Short-term Investments.
- Peak annual rise in Short-term Investments reached 1091.0% in 2025, while the deepest fall reached 88.51% in 2025.
- Tracing XOMA's Short-term Investments over 5 years: stood at $335000.0 in 2022, then plunged by 52.24% to $160000.0 in 2023, then surged by 731.25% to $1.3 million in 2024, then tumbled by 69.92% to $400000.0 in 2025, then climbed by 23.5% to $494000.0 in 2026.
- Business Quant data shows XOMA's Short-term Investments at $494000.0 in Q1 2026, $400000.0 in Q4 2025, and $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 494,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 17, 2025 | 5.24 Mn |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Sep 30, 2024 | 785,000.00 |
| Jun 30, 2024 | 696,000.00 |
| Mar 31, 2024 | 200,000.00 |
| Dec 31, 2023 | 160,000.00 |
| Sep 30, 2023 | 214,000.00 |
| Jun 30, 2023 | 320,000.00 |
| Mar 31, 2023 | 311,000.00 |
| Dec 31, 2022 | 335,000.00 |
| Sep 30, 2022 | 443,000.00 |
| Jun 30, 2022 | 523,000.00 |
| Mar 31, 2022 | 547,000.00 |
| Dec 31, 2021 | 2.05 Mn |
| Sep 30, 2021 | 3.42 Mn |
| Jun 30, 2021 | 2.31 Mn |